Bookmark and Share

Myung H Park
 

Myung H Park M.D.

Academic Title: Associate Professor
Primary Appointment: Medicine
Additional Title(s): Director, Pulmonary Vascular Diseases Program
mpark@medicine.umaryland.edu
Location: UMMC, S3B08
Phone: (410) 328-7260
Fax: (410) 328-1048

Research Interests:

Pulmonary Arterial Hypertension Studies, NIH Grant #1 RO1 HL078946-01 (Collaborator), 7/1/05 – 6/30/09
Pharmacogenomics in Pulmonary Arterial Hypertension. The major goal of this study is to determine clinically in PAH parients if associations exist between the efficacy and toxicity of bosentan, the most widely used therapy for PAH, and sitaxsentan, a new agent with the only ongoing large clinical trials with several gene polymorphisms in several key disease-specific and therapy-specific genes. Role:  PI

Actelion Clinical Operations AC0052-364, 12/1/05 – 11/29/08
EARLY:  Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Mildly Symptomatic Pulmoanry Arterial Hypertension. The major goal of this study is to demonstrate that bosentan improves cardiac hemodynamics and, as subordinate, exercise capacity in mildly symptomatic PAH patients. Role: PI

MD Primer, Inc. (Actelion, Inc.)/MOU, 3/21/06
PAH-QuERI Registry:  Pulmonary Arterial Hypertension Quality Enhancement Research Initiative. The major goal of this initiative is to facilitate access to published PAH guidelines by participating physicians and to allow them an opportunity of evaluating the applicability of the guidelines to their practice and ability to adhere to the guidelines as part of their patient management. Role:  PI

Co-Therix, Inx.  C200-006, Pending
VISION:  Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients with Pulmonary Arterial Hypertension receiving Oral Sildenafil..The primary goaal of this study is to assess the efficacy of the addition of inhaled iloprost vs. placebo in patients with PAH receiving sildenafil. Role: PI

Actelion, Inc.  AC-052-414, Pending
COMPASS 2:  Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients with Pulmonary Arterial Hypertension. The major goal is to demonstrate that the combination of bosentan and sildenafil prolongs the time to the first adjudicated morbidity/mortality event compared with sildenafil monotherapy in symptomatic patients with PAH. Role: PI

Co-Therix, Inc., Pending
REVEAL: Registry to Evaluate Early and Long-Term PAH Disease Management. The major goal is to characterize the demographics and clinical course of the patient population diagnosed with WHO Group I PAH. Role: PI


Publications: